International Stem Cell ISCO
OTC ISCO
$0.15 -0.02 (-11.76%)
At close: Oct 22, 2026 · 4:00 PM EDT

International Stem Cell (ISCO) Other Accumulated Expenses (2021)

Updated

International Stem Cell (ISCO) posted Other Accumulated Expenses of $300,000 for Q4 2021.

Analysis

International Stem Cell (ISCO) Other Accumulated Expenses (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn
10 International Stem Cell 1.20 Mn -2.77 Mn 1.46 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 300,000.00
API Access

International Stem Cell Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=ISCO&period=max&api_key=YOUR_API_KEY